private:piqurtherapeutics
|
3257645
|
May 31st, 2019 12:00AM
|
PIQUR Therapeutics AG
|
891
|
24.00
|
Open
|
Pharmaceuticals
|
May 30th, 2019 11:30PM
|
May 30th, 2019 11:30PM
|
PIQUR Therapeutics is a Swiss clinical-stage pharmaceutical company, incorporated in August 2011 as a spin-off of the University of Basel, focused on the discovery and development of innovative anti-cancer drugs based on the inhibition of lipid kinase (PI3K) and mTOR. PIQUR’s pipeline originates from one of the most promising research areas in oncology, as both PI3K and mTOR are clinically validated drug targets. The company holds a worldwide exclusive license on the intellectual property rights for development and commercialization of Bimiralisib and related series of analogues. For more information, please visit www.piqur.com
|
Open
|
Oncology, Small Molecules, Hematology, Drug Development
|
Open
|
Hochbergerstrasse 60C
|
Basel
|
|
CH
|
CH-4057
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 17th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 17th, 2018 02:25PM
|
Feb 17th, 2018 02:25PM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 16th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 16th, 2017 08:15AM
|
Feb 16th, 2017 08:15AM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 15th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 15th, 2017 10:07AM
|
Feb 15th, 2017 10:07AM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 14th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 14th, 2017 01:50PM
|
Feb 14th, 2017 01:50PM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 13th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 13th, 2017 04:11PM
|
Feb 13th, 2017 04:11PM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 12th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 12th, 2017 04:15AM
|
Feb 12th, 2017 04:15AM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 11th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 11th, 2017 05:35AM
|
Feb 11th, 2017 05:35AM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 10th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 10th, 2017 06:43AM
|
Feb 10th, 2017 06:43AM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|
private:piqurtherapeutics
|
3257645
|
Feb 9th, 2018 12:00AM
|
PIQUR Therapeutics AG
|
535
|
29.00
|
Open
|
Pharmaceuticals
|
Feb 9th, 2017 08:57AM
|
Feb 9th, 2017 08:57AM
|
PIQUR is a Swiss clinical-stage pharmaceutical company incorporated in August 2011 as a spin-off of the Basel University focusing on the discovery and development of innovative anti-cancer drugs based on lipid kinase (PI3K) and mTOR inhibition. PIQUR’s pipeline originates from one of the most promising research areas in oncology. PIQUR’s lead candidate, PQR309, has successfully concluded the first Phase 1 trial. The initial results indicate that PQR309 is well-tolerated with no significant side effects and meets the primary endpoints of safety and tolerability. Furthermore, PQR309 demonstrated clear biologic activity and first promising signs of clinical activity. In Q2/2015, PIQUR has started Phase 2 trials with PQR309 in selected cancer indications.
|
|
|
|
|
|
|
|
|
|
PIQUR Therapeutics
|
|
Health Care Equipment & Services
|